An interventional study of Blood sample and Geriatric assessment standardized in Chronic Kidney Failure, Frailty and Aging, sponsored by University Hospital, Bordeaux. Not yet recruiting at 3 sites in France. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2025-03-20.
Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 145 studies in Kidney Failure, Chronic with a site in France — 28 open to participants now, 33 under way, 6 of them phase 3. Kidney Failure, Chronic · France.
Among the 145 studies in Kidney Failure, Chronic with a site in France, this one is the 61st largest by planned enrollment of the 105 interventional ones that give a count, is one of 4 that started in 2025, is one of 55 with no phase, reaches primary completion later than 14 of the 32 other live ones, and was the 140th registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →28 of the 145 studies in Kidney Failure, Chronic with a site in France are open now. Recruiting first, the newest first:
Central Hospital, Nancy, France · Sites in France
Ages 18+ · Healthy volunteers
University of Avignon · Sites in France
Ages 20–79
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Centre Hospitalier Régional d'Orléans · Sites in France
Ages 18+ · Healthy volunteers
Hospices Civils de Lyon · Sites in France
Ages 6–17 · Men only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
145 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 16 · Phase 3 26 · Phase 4 9
First in 1994; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 70 across the 105 interventional studies, 177 across the 40 observational. Of the 90 that completed or were terminated, 15 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 145 have an industry lead sponsor. The 10 most frequent:
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
University Hospital, Bordeaux has 6 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
7 of the studies in Kidney Failure, Chronic with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06692231Centre Hospitalier de VichyImpact of Hospital Pharmacist Intervention on Medication Management in Dialysis Patients | 2026-11-30 |
| NCT06474169Centre Hospitalier Régional d'OrléansAssessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients. | 2026-12 |
| NCT06595680Hospices Civils de LyonDevelopment of an Innovative Hemodialysis Method to Improve Dialytic Clearance of Protein-bound Uremic Toxins | 2027-01-22 |
| NCT06887075University Hospital, BordeauxSystemic Activation of Inflammasomes and Frailty in Older Candidates to Kidney Transplantation | 2027-02-15 |
| NCT05753930Hansa Biopharma ABImlifidase Prior to Kidney Transplant in Highly Sensitised Children | 2027-02-28 |
Add all 7 to your calendar (.ics) → With an account.
Among the 145 studies in Kidney Failure, Chronic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Kidney transplantation (KT) benefit-risk ratio assessment is a challenge in a growing population of older patients with end-stage kidney disease. A pre-KT frailty phenotype has been found predictive of post-KT complications, but biological mechanisms of frailty are poorly known is these patients. Frailty is associated with chronic low-grade inflammation in the older general population, possibly through the inflammasome pathway. Our main objective is to assess if systemic activation of inflammasomes is associated with frailty in older candidates to KT.
Kidney transplantation (KT) benefit-risk ratio assessment is a challenge in a growing population of older patients with end-stage kidney disease. Chronic low-grade inflammation is a hallmark of biological aging and is associated with age-related diseases and frailty. Frailty is conceptually defined as an agerelated reduction in physiological reserve increasing vulnerability to stressors. A pre-KT frailty phenotype is associated with post-KT complications, including re-hospitalizations, delayed graft function, delirium and 5-year mortality. Taking pre-KT inflammation into account (serum level of CRP, IL6, sTNFR1) improves prediction of mortality on KT waiting-list, independently of comorbidity.
Molecular and cellular pathways of this inflammation are poorly known, and may involve inflammasomes. Inflammasomes are intra-cellular protein complexes whose assembly, upon stress signals, triggers maturation and release of pro-inflammatory cytokines named interleukine (IL)-1 and IL-18. Inflammasomes are involved in locomotor, cognitive and immune aging in mice, and systemic expression of inflammasomes genes is associated with mortality in older humans. Data is lacking about systemic activation of inflammasomes in older patients with end-stage kidney disease. Our main objective is to assess if pre-KT systemic activation of inflammasomes is associated with frailty in older candidates to KT.
We will measure systemic activation of inflammasomes in peripheral blood of older candidates to KT using cytokine bead-based multiplex assay, Single Molecule Array, intra-cytoplasmic staining, flow cytometry and RT-qPCR in peripheral blood mononuclear cells. Frailty will be measured using validated standardized criteria. A frailty phenotype is defined by at least 3 of the following criteria:
weight loss, exhaustion, muscle weakness, low physical activity, low gait speed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age ≥ 70
Inclusion in an industrial study refusing co-inclusion in our study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Frailty will be measured clinically using reference criteria in the general population and validated in Kidney Transplantation (KT), i.e. predictive of post-KT complications: delayed recovery of graft function, graft function, early re-hospitalization, occurrence of post-operative confusion, mortality. Fragile patients present at least 3 out of 5 criteria
Biological: Blood sample · Behavioral: Geriatric assessment standardized
Patients will be considered non-fragile if they present 0 to 2 criteria
Biological: Blood sample · Behavioral: Geriatric assessment standardized
* Immunophenotyping of peripheral lymphocytes, with a focus on proportions of naïve / central memory / effector memory / TEMRA cells, and markers of activation and senescence * Serum inflammatory markers : CRP, IL-6, MCP-1, TNF, sTNFR1 * Single Molecule Array for IL1 and LUMINEX for IL18 in patient's sera * RT-qPCR for inflammasomes genes (NLRP3, NLRC4, NLRC5, AIM2, ASC, casp1, IL1b, IL18) expression among peripheral blood mononuclear cells * Assembly of the inflammasome platform will be measured in monocytes using intra-cellular staining of the ASC protein and flow cytometry
* Exhaustion (2 standardized questions) * Physical activity \<383 kcal/week (men) or \<270 kcal/week (women), measured using a standardized questionnaire (IPAQ) * 4-meters gait speed, with sex and height-specific cutoffs * Handgrip strength, measured using a dynamometer, with sex and BMI-sp Comorbidity (CIRS-G score ) * Screening for intrinsic capacity decline (first step of ICOPE program, adapted to the study, ) * Physical performance (SPPB score ) * Cognitive functions (MoCA score ), * Depression (GDS-15 score ), * Nutrition (MNA score ) * Sensory functions (Snellen test for vision, HHIES questionnaire for hearing) -- Dependency in activities of daily living (ADL and IADL scores)
IL1
Single Molecule Array for IL1
Time frame: at recruitment (up to 30 days)
IL18
LUMINEX for IL18 in patient's sera
Time frame: at recruitment (up to 30 days)
inflammasomes genes
RT-qPCR for inflammasomes genes (NLRP3, NLRC4, NLRC5, AIM2, ASC, casp1, IL1b, IL18) expression among peripheral blood mononuclear cells
Time frame: at recruitment (up to 30 days)
inflammasome platform
Assembly of the inflammasome platform will be measured in monocytes using intra-cellular staining of the ASC protein and flow cytometry
Time frame: at recruitment (up to 30 days)
Weight
Frailty phenotype : Weight loss (unintentional, \>4,5 kg during past year)
Time frame: at enrollment (Day 0), at recruitment (up to 30 days)
Activity
Frailty phenotype : Physical activity \<383 kcal/week (men) or \<270 kcal/week (women), measured using a standardized questionnaire (IPAQ)
Time frame: at enrollment (Day 0), at recruitment (up to 30 days)
Gait
Frailty phenotype : 4-meters gait speed, with sex and height-specific cutoffs
Time frame: at enrollment (day 0), at recruitment (up to 30 days)
Handgrip strength
Frailty phenotype : Handgrip strength, measured using a dynamometer, with sex and BMI-specific cutoffs
Time frame: at enrollment (day 0), at recruitment (up to 30 days)
Comorbidity
Comorbidity : Cumulative Illness Rating Scale (CIRS-G score)
Time frame: at recruitment (up to 30 days)
decline
Screening for intrinsic capacity decline : first step of ICOPE program, adapted to the study
Time frame: at recruitment (up to 30 days)
Physical performance
Physical performance : Short Physical Performance Battery (SPPB) score. The SPPB (Short Physical Performance Battery) is the sum of scores on three criteria: the balance test, the walking speed test and the chair lift test. This test assesses an individual's physical performance. The sum of the scores for all the tests gives an overall performance score. A score below 8 indicates a risk of sarcopenia (or age-related muscular dystrophy).
Time frame: at recruitment (up to 30 days)
Cognitive functions
Cognitive functions : Score Montreal Cognitive Assessment (MoCA) score The Montreal Cognitive Assessement (MoCA) is the most sensitive rapid assessment test, providing the most comprehensive evaluation (attention, concentration, executive functions, memory, language, capacitive-vesuo-constructive, abstraction, calculation, orientation) cognitive functions. It is tending to replace the MMSE in clinical practice. A score of 26 (25 if cultural level ≤3 = primary diploma = CEP) is considered abnormal.
Time frame: at recruitment (up to 30 days)
Depression
Depression : Geriatric Depression Scale (GDS-15 score) 0 - 5 points: normal 5-10 points: mild to moderate depression 11-15 points: severe depression
Time frame: at recruitment (up to 30 days)
Nutrition
Nutrition : Mini Nutritional Assessment (MNA score) * 12-14 points: MNA score indicates normal nutritional status. * 8-11 points: the MNA score indicates a risk of malnutrition. * 0-7 points: MNA score indicates malnutrition.
Time frame: at recruitment (up to 30 days)
Snellen test
Sensory functions : Snellen test for vision
Time frame: at recruitment (up to 30 days)
ADL
Dependency in activities of daily living : Activities of Daily Living ADL The original ADL scale scores each of the 6 items in 0/1, with 1 corresponding to independence and 0 to dependence. The total score ranges from 0 to 6. An overall score can be calculated, ranging from 0 (totally dependent) to 6 (best possible independence).
Time frame: at recruitment (up to 30 days)
Immunophenotyping
Immunophenotyping of peripheral lymphocytes, with a focus on proportions of naïve / central memory / effector memory / TEMRA cells, and markers of activation and senescence
Time frame: at recruitment (up to 30 days)
CRP
Serum inflammatory markers : CRP
Time frame: at recruitment (up to 30 days)
IL-6
Serum inflammatory markers : IL-6
Time frame: at recruitment (up to 30 days)
MCP-1
Serum inflammatory markers : MCP-1
Time frame: at recruitment (up to 30 days)
TNF
Serum inflammatory markers : TNF
Time frame: at recruitment (up to 30 days)
sTNFR1
Serum inflammatory markers : sTNFR1
Time frame: at recruitment (up to 30 days)
HHIES questionnaire
Sensory functions : Hearing Handicap Inventory for the Elderly Screening (HHIES) questionnaire for hearing. The higher the score, the greater the likelihood of hearing loss
Time frame: at recruitment (up to 30 days)
IADL
Dependency in activities of daily living : IADL scores
Time frame: at recruitment (up to 30 days)
Start is estimated for Apr 2025; primary completion for Feb 2027, 22 months later.
Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 22 months is close to that.
Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →